Home › NCT07348627

Opioid-Sparing Joint Replacement

Opioid-Sparing Joint Replacement - Single Site Randomized Control Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of hip osteoarthritis requiring primary arthroplasty
* Scheduled to undergo anterior total hip arthroplasty (THA)
* Able to comply with study procedures and follow-up visits
* Able to provide informed consent

Exclusion Criteria:

* Concurrent significant injuries to other bones or organs
* Local infection at or near the surgical site
* Preoperative opioid use within 4 weeks prior to surgery
* History of severe heart disease (NYHA Class II or higher), renal failure, or liver dysfunction
* Chronic liver disease
* Neurological or psychiatric conditions that may influence pain perception
* Pregnancy
* History of alcohol or medication abuse
* Inability to take NSAIDs
* Use of postoperative DVT prophylaxis other than aspirin 81 mg twice daily
* Diabetes mellitus with HbA1c \> 8.0%
* Diagnosis of chronic pain syndrome or fibromyalgia
* Pain Catastrophizing Scale (PCS) score \> 29
* Any condition that, in the investigator's judgment, may interfere with adherence to study procedures or follow-up

About the study

The goal of this clinical trial is to evaluate whether an opioid-sparing postoperative pain regimen can reduce opioid consumption and maintain effective pain control in adults undergoing anterior total hip arthroplasty for osteoarthritis.

The main questions it aims to answer are:

* Does an opioid-limited regimen result in lower postoperative opioid use compared with a standard opioid prescription? * Does the opioid-limited regimen provide comparable or improved postoperative pain control and patient satisfaction?

What is being tested

• Placebo (drug)
• Oxycodone 5 mg (drug)
• Multimodal Non-Opioid Analgesia (other)

Sponsor: Emory University · Participants: 120 · Started: Mar 19, 2026

Contact the study team

• Ajay Premkumar, MD · Phone: 404-778-3350

Official record on ClinicalTrials.gov — NCT07348627

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.